Thomas Meyer
Concepts (486)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Water | 29 | 2020 | 469 | 7.220 |
Why?
| | Ruthenium | 22 | 2020 | 34 | 5.200 |
Why?
| | Organometallic Compounds | 21 | 2014 | 112 | 4.360 |
Why?
| | Catalysis | 29 | 2020 | 322 | 2.710 |
Why?
| | Oxidation-Reduction | 41 | 2020 | 1087 | 2.550 |
Why?
| | Protons | 12 | 2016 | 95 | 2.430 |
Why?
| | Electron Transport | 16 | 2016 | 118 | 2.030 |
Why?
| | Titanium | 10 | 2013 | 81 | 2.000 |
Why?
| | Electrodes | 13 | 2020 | 114 | 1.710 |
Why?
| | Oxygen | 8 | 2020 | 995 | 1.420 |
Why?
| | Electrochemistry | 14 | 2017 | 73 | 1.410 |
Why?
| | Electron Transport Complex IV | 4 | 2016 | 62 | 1.320 |
Why?
| | Electrochemical Techniques | 7 | 2020 | 55 | 1.310 |
Why?
| | Alu Elements | 5 | 2025 | 29 | 1.240 |
Why?
| | Coordination Complexes | 6 | 2020 | 13 | 1.220 |
Why?
| | Electrons | 9 | 2013 | 88 | 1.180 |
Why?
| | Tin Compounds | 5 | 2020 | 17 | 1.150 |
Why?
| | Molecular Structure | 18 | 2014 | 499 | 1.130 |
Why?
| | Photochemical Processes | 6 | 2013 | 108 | 1.020 |
Why?
| | 2,2'-Dipyridyl | 3 | 2013 | 7 | 1.010 |
Why?
| | Models, Chemical | 6 | 2013 | 269 | 1.010 |
Why?
| | Hylobates | 3 | 2016 | 8 | 0.980 |
Why?
| | Solar Energy | 4 | 2013 | 34 | 0.980 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2024 | 99 | 0.830 |
Why?
| | Chlorides | 2 | 2015 | 142 | 0.810 |
Why?
| | Surface Properties | 10 | 2017 | 410 | 0.800 |
Why?
| | Copper | 2 | 2015 | 113 | 0.780 |
Why?
| | Benzoquinones | 2 | 2014 | 47 | 0.770 |
Why?
| | Amides | 2 | 2014 | 101 | 0.750 |
Why?
| | Oligopeptides | 3 | 2013 | 269 | 0.740 |
Why?
| | Long Interspersed Nucleotide Elements | 3 | 2022 | 32 | 0.740 |
Why?
| | Nanostructures | 3 | 2013 | 117 | 0.740 |
Why?
| | Pyridines | 5 | 2013 | 605 | 0.740 |
Why?
| | Coloring Agents | 3 | 2020 | 93 | 0.730 |
Why?
| | Peptides | 5 | 2014 | 995 | 0.660 |
Why?
| | Polymers | 2 | 2017 | 499 | 0.660 |
Why?
| | Ammonia | 2 | 2019 | 65 | 0.620 |
Why?
| | Metal Nanoparticles | 4 | 2015 | 85 | 0.610 |
Why?
| | Osmium | 2 | 2013 | 3 | 0.600 |
Why?
| | Nitrogen Cycle | 1 | 2019 | 11 | 0.590 |
Why?
| | Kinetics | 11 | 2014 | 1627 | 0.580 |
Why?
| | Papillomavirus Infections | 4 | 2025 | 345 | 0.580 |
Why?
| | Paracoccus denitrificans | 2 | 2015 | 3 | 0.560 |
Why?
| | Genome | 8 | 2018 | 306 | 0.550 |
Why?
| | Retroelements | 7 | 2025 | 51 | 0.550 |
Why?
| | Enzymes, Immobilized | 2 | 2015 | 30 | 0.540 |
Why?
| | Photochemistry | 5 | 2012 | 134 | 0.530 |
Why?
| | Gold | 3 | 2015 | 115 | 0.520 |
Why?
| | Photosynthesis | 4 | 2014 | 98 | 0.510 |
Why?
| | Light | 3 | 2020 | 411 | 0.500 |
Why?
| | Minisatellite Repeats | 1 | 2016 | 36 | 0.500 |
Why?
| | Phylogeny | 4 | 2014 | 1016 | 0.490 |
Why?
| | Hydroquinones | 2 | 2012 | 29 | 0.460 |
Why?
| | Thermus thermophilus | 2 | 2014 | 21 | 0.450 |
Why?
| | Silver | 1 | 2015 | 38 | 0.430 |
Why?
| | Hydrogen-Ion Concentration | 6 | 2015 | 561 | 0.430 |
Why?
| | Chlorine | 1 | 2015 | 64 | 0.430 |
Why?
| | Cytochrome b Group | 1 | 2014 | 22 | 0.430 |
Why?
| | Oxides | 2 | 2013 | 51 | 0.420 |
Why?
| | Proline | 3 | 2013 | 83 | 0.420 |
Why?
| | Ferric Compounds | 1 | 2014 | 55 | 0.400 |
Why?
| | NAD | 1 | 2014 | 81 | 0.400 |
Why?
| | Fluorine | 1 | 2013 | 17 | 0.400 |
Why?
| | Polystyrenes | 1 | 2013 | 37 | 0.390 |
Why?
| | Carbon Dioxide | 2 | 2012 | 242 | 0.390 |
Why?
| | Cobalt | 1 | 2013 | 53 | 0.390 |
Why?
| | Biofuels | 1 | 2012 | 16 | 0.380 |
Why?
| | Singlet Oxygen | 1 | 2012 | 18 | 0.380 |
Why?
| | Polymerization | 1 | 2013 | 130 | 0.380 |
Why?
| | Ruthenium Compounds | 2 | 2010 | 2 | 0.370 |
Why?
| | Benzyl Alcohol | 1 | 2012 | 12 | 0.360 |
Why?
| | Diphosphonates | 1 | 2012 | 68 | 0.360 |
Why?
| | Carbon Monoxide | 1 | 2012 | 82 | 0.360 |
Why?
| | Hydroxides | 1 | 2011 | 26 | 0.360 |
Why?
| | Cytochromes c1 | 1 | 2011 | 1 | 0.350 |
Why?
| | Cytochrome c Group | 1 | 2011 | 43 | 0.340 |
Why?
| | Papillomaviridae | 2 | 2019 | 115 | 0.330 |
Why?
| | Indium | 1 | 2010 | 8 | 0.330 |
Why?
| | Photosystem II Protein Complex | 2 | 2007 | 16 | 0.320 |
Why?
| | Tin | 1 | 2010 | 9 | 0.320 |
Why?
| | Photolysis | 1 | 2011 | 94 | 0.320 |
Why?
| | Tryptophan | 1 | 2011 | 181 | 0.320 |
Why?
| | Nitrogen | 2 | 2019 | 170 | 0.310 |
Why?
| | Nanoparticles | 3 | 2013 | 519 | 0.290 |
Why?
| | Models, Molecular | 7 | 2013 | 1618 | 0.290 |
Why?
| | Lung Neoplasms | 6 | 2024 | 2637 | 0.280 |
Why?
| | Recombination, Genetic | 4 | 2016 | 205 | 0.260 |
Why?
| | Signal Transduction | 4 | 2025 | 5226 | 0.250 |
Why?
| | Molecular Conformation | 5 | 2013 | 148 | 0.240 |
Why?
| | Human papillomavirus 16 | 1 | 2025 | 27 | 0.230 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2025 | 41 | 0.230 |
Why?
| | Myelin Proteins | 2 | 2016 | 45 | 0.230 |
Why?
| | Interleukin-7 | 1 | 2025 | 65 | 0.230 |
Why?
| | Deoxycytidine | 4 | 2014 | 221 | 0.220 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2025 | 56 | 0.220 |
Why?
| | Cottontail rabbit papillomavirus | 1 | 2024 | 3 | 0.220 |
Why?
| | Energy Transfer | 3 | 2013 | 49 | 0.210 |
Why?
| | ras Proteins | 1 | 2025 | 150 | 0.210 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2024 | 21 | 0.210 |
Why?
| | Mood Disorders | 1 | 2025 | 140 | 0.210 |
Why?
| | Rhadinovirus | 1 | 2024 | 20 | 0.200 |
Why?
| | RNA, Transfer | 1 | 2025 | 144 | 0.200 |
Why?
| | Solvents | 1 | 2004 | 113 | 0.200 |
Why?
| | Animals | 24 | 2025 | 38058 | 0.200 |
Why?
| | Herpesvirus 8, Human | 1 | 2024 | 68 | 0.200 |
Why?
| | Gammaherpesvirinae | 1 | 2024 | 45 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1953 | 0.200 |
Why?
| | Sarcoma, Kaposi | 1 | 2024 | 83 | 0.190 |
Why?
| | DNA Repair | 1 | 2025 | 256 | 0.190 |
Why?
| | RNA, Long Noncoding | 1 | 2025 | 177 | 0.190 |
Why?
| | Amines | 1 | 2003 | 39 | 0.190 |
Why?
| | Genome-Wide Association Study | 3 | 2021 | 1406 | 0.190 |
Why?
| | Janus Kinases | 1 | 2023 | 20 | 0.190 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 143 | 0.190 |
Why?
| | Evolution, Molecular | 6 | 2014 | 514 | 0.190 |
Why?
| | Herpesviridae Infections | 1 | 2024 | 150 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 101 | 0.180 |
Why?
| | Luminescence | 2 | 2012 | 39 | 0.180 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2025 | 267 | 0.180 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 132 | 0.180 |
Why?
| | Interferon Type I | 1 | 2023 | 145 | 0.180 |
Why?
| | Stress, Physiological | 1 | 2025 | 453 | 0.170 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 108 | 0.170 |
Why?
| | Withanolides | 1 | 2021 | 2 | 0.170 |
Why?
| | Spectrophotometry | 2 | 2012 | 61 | 0.170 |
Why?
| | Poly I-C | 1 | 2021 | 57 | 0.170 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 458 | 0.170 |
Why?
| | Lasers | 2 | 2012 | 132 | 0.170 |
Why?
| | Thermodynamics | 4 | 2007 | 426 | 0.170 |
Why?
| | Mutation | 4 | 2021 | 4089 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2004 | 247 | 0.170 |
Why?
| | Hydrogen Bonding | 3 | 2016 | 169 | 0.160 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2021 | 84 | 0.160 |
Why?
| | Quantum Theory | 2 | 2011 | 93 | 0.160 |
Why?
| | DNA Transposable Elements | 2 | 2014 | 122 | 0.160 |
Why?
| | Biomimetics | 1 | 2020 | 40 | 0.160 |
Why?
| | Edetic Acid | 1 | 2020 | 47 | 0.160 |
Why?
| | Skin Neoplasms | 2 | 2024 | 847 | 0.160 |
Why?
| | Sodium Nitrite | 1 | 2020 | 39 | 0.150 |
Why?
| | Circular Dichroism | 2 | 2013 | 150 | 0.150 |
Why?
| | HMGN1 Protein | 1 | 2018 | 1 | 0.150 |
Why?
| | Mitochondria, Heart | 1 | 2019 | 102 | 0.150 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1180 | 0.140 |
Why?
| | Immunotherapy | 2 | 2021 | 653 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 641 | 0.140 |
Why?
| | alpha-Synuclein | 1 | 2019 | 46 | 0.140 |
Why?
| | Transcription Factors | 3 | 2022 | 1741 | 0.140 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2930 | 0.140 |
Why?
| | Blood | 1 | 2019 | 109 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 881 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 427 | 0.140 |
Why?
| | Humans | 37 | 2025 | 144759 | 0.140 |
Why?
| | Genetic Variation | 3 | 2014 | 983 | 0.130 |
Why?
| | Biological Products | 1 | 2021 | 252 | 0.130 |
Why?
| | Buffers | 1 | 2017 | 55 | 0.130 |
Why?
| | Imidazoles | 1 | 2018 | 254 | 0.130 |
Why?
| | Cytoskeletal Proteins | 2 | 2016 | 156 | 0.130 |
Why?
| | Crystallography, X-Ray | 2 | 2013 | 492 | 0.130 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 628 | 0.130 |
Why?
| | Pseudomonas stutzeri | 1 | 2016 | 2 | 0.130 |
Why?
| | Cholesterol | 2 | 2021 | 406 | 0.130 |
Why?
| | Rhodobacter sphaeroides | 1 | 2016 | 7 | 0.130 |
Why?
| | Vibrio cholerae | 1 | 2016 | 14 | 0.120 |
Why?
| | Mice | 11 | 2025 | 18339 | 0.120 |
Why?
| | Proteins | 2 | 2016 | 1021 | 0.120 |
Why?
| | Munc18 Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Genome, Human | 3 | 2025 | 422 | 0.120 |
Why?
| | Electric Power Supplies | 2 | 2013 | 52 | 0.120 |
Why?
| | Neurons | 2 | 2022 | 1640 | 0.120 |
Why?
| | Phenothiazines | 2 | 2006 | 8 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 586 | 0.110 |
Why?
| | Silver Compounds | 1 | 2015 | 5 | 0.110 |
Why?
| | Potentiometry | 2 | 2016 | 4 | 0.110 |
Why?
| | Cerium | 1 | 2015 | 19 | 0.110 |
Why?
| | Chemical Precipitation | 1 | 2015 | 39 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2018 | 499 | 0.110 |
Why?
| | Carbonates | 1 | 2015 | 11 | 0.110 |
Why?
| | HeLa Cells | 1 | 2016 | 650 | 0.110 |
Why?
| | Karyotype | 1 | 2014 | 19 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2014 | 44 | 0.110 |
Why?
| | Solutions | 1 | 2015 | 166 | 0.110 |
Why?
| | Pan troglodytes | 3 | 2008 | 63 | 0.100 |
Why?
| | Macaca mulatta | 2 | 2022 | 191 | 0.100 |
Why?
| | Time Factors | 4 | 2013 | 7173 | 0.100 |
Why?
| | Fluorouracil | 3 | 2010 | 235 | 0.100 |
Why?
| | Enzyme Activation | 1 | 2015 | 766 | 0.100 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 684 | 0.100 |
Why?
| | Ions | 1 | 2013 | 71 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 889 | 0.100 |
Why?
| | Survival Analysis | 5 | 2014 | 1382 | 0.100 |
Why?
| | Phosphoric Acids | 1 | 2012 | 17 | 0.090 |
Why?
| | Particle Size | 2 | 2011 | 411 | 0.090 |
Why?
| | Strepsirhini | 1 | 2012 | 2 | 0.090 |
Why?
| | Tantalum | 1 | 2012 | 3 | 0.090 |
Why?
| | Brain | 2 | 2022 | 2933 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2013 | 103 | 0.090 |
Why?
| | Anthracenes | 1 | 2012 | 31 | 0.090 |
Why?
| | Acrylates | 1 | 2012 | 48 | 0.090 |
Why?
| | Asia, Southeastern | 1 | 2012 | 13 | 0.090 |
Why?
| | Pancreatic Neoplasms | 2 | 2014 | 919 | 0.090 |
Why?
| | Mutagenesis, Insertional | 1 | 2012 | 64 | 0.090 |
Why?
| | Luminescent Agents | 1 | 2012 | 8 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5992 | 0.090 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 179 | 0.090 |
Why?
| | Iridium | 1 | 2011 | 7 | 0.090 |
Why?
| | Quartz Crystal Microbalance Techniques | 1 | 2011 | 7 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 295 | 0.090 |
Why?
| | Semiconductors | 1 | 2011 | 38 | 0.090 |
Why?
| | Geography | 1 | 2012 | 203 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2014 | 285 | 0.090 |
Why?
| | Selenium Compounds | 1 | 2011 | 18 | 0.090 |
Why?
| | Biology | 1 | 2012 | 91 | 0.090 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 259 | 0.090 |
Why?
| | Data Mining | 1 | 2012 | 117 | 0.080 |
Why?
| | Cadmium Compounds | 1 | 2011 | 31 | 0.080 |
Why?
| | Genetic Loci | 1 | 2012 | 261 | 0.080 |
Why?
| | Ligands | 3 | 2016 | 673 | 0.080 |
Why?
| | Glutamates | 1 | 2011 | 66 | 0.080 |
Why?
| | Prevalence | 4 | 2022 | 2834 | 0.080 |
Why?
| | Rabbits | 2 | 2024 | 648 | 0.080 |
Why?
| | DNA-Binding Proteins | 3 | 2025 | 1499 | 0.080 |
Why?
| | Cytokines | 1 | 2018 | 2061 | 0.080 |
Why?
| | Guanine | 1 | 2011 | 87 | 0.080 |
Why?
| | Carboplatin | 1 | 2011 | 160 | 0.080 |
Why?
| | Mice, Nude | 3 | 2021 | 682 | 0.080 |
Why?
| | Female | 18 | 2025 | 78271 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2014 | 1137 | 0.080 |
Why?
| | Organoplatinum Compounds | 1 | 2010 | 66 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2025 | 3121 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 630 | 0.080 |
Why?
| | Dimerization | 1 | 2010 | 194 | 0.080 |
Why?
| | Leucovorin | 1 | 2010 | 101 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2016 | 955 | 0.080 |
Why?
| | Phosphorylation | 3 | 2025 | 1732 | 0.080 |
Why?
| | DNA, Viral | 2 | 2019 | 358 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 680 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1907 | 0.070 |
Why?
| | Aged | 11 | 2024 | 25913 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1054 | 0.070 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2008 | 5 | 0.070 |
Why?
| | Chromosome Inversion | 1 | 2008 | 19 | 0.070 |
Why?
| | Metals | 1 | 2010 | 142 | 0.070 |
Why?
| | Chromosomes | 1 | 2008 | 108 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3540 | 0.070 |
Why?
| | Stereoisomerism | 2 | 2011 | 104 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 681 | 0.070 |
Why?
| | Radiotherapy, Conformal | 2 | 2006 | 74 | 0.070 |
Why?
| | Membranes | 1 | 2007 | 13 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 985 | 0.070 |
Why?
| | Hydrogen | 1 | 2008 | 73 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2363 | 0.070 |
Why?
| | Middle Aged | 11 | 2024 | 35875 | 0.070 |
Why?
| | Cercopithecidae | 1 | 2007 | 8 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 654 | 0.060 |
Why?
| | Enzymes | 1 | 2007 | 65 | 0.060 |
Why?
| | Male | 15 | 2024 | 72315 | 0.060 |
Why?
| | Down-Regulation | 2 | 2020 | 627 | 0.060 |
Why?
| | Pyrazoles | 1 | 2011 | 509 | 0.060 |
Why?
| | Temperature | 1 | 2010 | 679 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1519 | 0.060 |
Why?
| | Bronchogenic Cyst | 1 | 2006 | 8 | 0.060 |
Why?
| | Barotrauma | 1 | 2006 | 4 | 0.060 |
Why?
| | Explosions | 1 | 2006 | 15 | 0.060 |
Why?
| | Luminescent Measurements | 2 | 2003 | 76 | 0.060 |
Why?
| | Embolism, Air | 1 | 2006 | 14 | 0.060 |
Why?
| | Aircraft | 1 | 2006 | 23 | 0.060 |
Why?
| | Database Management Systems | 1 | 2006 | 50 | 0.060 |
Why?
| | Intracranial Embolism | 1 | 2006 | 34 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2010 | 582 | 0.060 |
Why?
| | Tetrazoles | 1 | 2006 | 50 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2323 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2194 | 0.060 |
Why?
| | Tyrosine | 1 | 2006 | 222 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 779 | 0.060 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2016 | 85 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2025 | 4154 | 0.060 |
Why?
| | Acetyltransferases | 1 | 2025 | 21 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2024 | 11679 | 0.060 |
Why?
| | Databases, Genetic | 1 | 2006 | 248 | 0.060 |
Why?
| | Gene Knockout Techniques | 1 | 2025 | 116 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2007 | 321 | 0.060 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2004 | 20 | 0.050 |
Why?
| | Gene Library | 1 | 2025 | 126 | 0.050 |
Why?
| | Isotopes | 1 | 2004 | 34 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2025 | 2050 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4557 | 0.050 |
Why?
| | Hydroxylamines | 1 | 2024 | 8 | 0.050 |
Why?
| | Anthraquinones | 1 | 2004 | 10 | 0.050 |
Why?
| | Oxadiazoles | 1 | 2024 | 37 | 0.050 |
Why?
| | Acetylation | 1 | 2025 | 252 | 0.050 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 2 | 2016 | 88 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 109 | 0.050 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2024 | 46 | 0.050 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2024 | 35 | 0.050 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 570 | 0.050 |
Why?
| | Indicators and Reagents | 1 | 2003 | 106 | 0.050 |
Why?
| | Iron | 1 | 2006 | 359 | 0.050 |
Why?
| | Ribosomes | 1 | 2025 | 191 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2007 | 592 | 0.050 |
Why?
| | Haplotypes | 1 | 2025 | 490 | 0.050 |
Why?
| | Phthalazines | 1 | 2024 | 64 | 0.050 |
Why?
| | Virus Latency | 1 | 2024 | 90 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2010 | 780 | 0.050 |
Why?
| | Purines | 1 | 2004 | 187 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2027 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2004 | 369 | 0.050 |
Why?
| | Bile Duct Neoplasms | 1 | 2004 | 127 | 0.050 |
Why?
| | Topotecan | 1 | 2003 | 17 | 0.050 |
Why?
| | Nitrogen Isotopes | 1 | 2003 | 72 | 0.050 |
Why?
| | Phenazines | 1 | 2002 | 16 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 24 | 0.050 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2023 | 35 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2022 | 1095 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2003 | 97 | 0.050 |
Why?
| | Genome, Viral | 1 | 2024 | 218 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 176 | 0.050 |
Why?
| | Biodiversity | 1 | 2006 | 426 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 237 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2003 | 212 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2847 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 170 | 0.050 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2006 | 291 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1253 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2024 | 207 | 0.040 |
Why?
| | Nucleic Acid Conformation | 1 | 2025 | 726 | 0.040 |
Why?
| | Chromosomal Instability | 1 | 2021 | 21 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2023 | 197 | 0.040 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 845 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 55 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 928 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 423 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2430 | 0.040 |
Why?
| | Endosomes | 1 | 2023 | 140 | 0.040 |
Why?
| | Fallopian Tubes | 1 | 2021 | 33 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 549 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2025 | 523 | 0.040 |
Why?
| | Interferon Inducers | 1 | 2021 | 8 | 0.040 |
Why?
| | Gene Transfer, Horizontal | 2 | 2014 | 35 | 0.040 |
Why?
| | Glutamine | 1 | 2021 | 109 | 0.040 |
Why?
| | Piperazines | 1 | 2024 | 381 | 0.040 |
Why?
| | Adult | 7 | 2024 | 40449 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2004 | 627 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 457 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2021 | 157 | 0.040 |
Why?
| | Europe | 1 | 2022 | 412 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 688 | 0.040 |
Why?
| | Stents | 1 | 2004 | 556 | 0.040 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1266 | 0.040 |
Why?
| | Germany | 2 | 2014 | 138 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2011 | 8265 | 0.040 |
Why?
| | Apelin | 1 | 2019 | 10 | 0.040 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 16 | 0.040 |
Why?
| | Histones | 1 | 2025 | 669 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 177 | 0.040 |
Why?
| | Nitrites | 1 | 2020 | 89 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1257 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2019 | 59 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 151 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 374 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2608 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 919 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2029 | 0.040 |
Why?
| | Neoadjuvant Therapy | 2 | 2014 | 462 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2003 | 300 | 0.040 |
Why?
| | Nuclear Localization Signals | 1 | 2019 | 17 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 187 | 0.040 |
Why?
| | Synteny | 1 | 2018 | 14 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 196 | 0.040 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 234 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2011 | 289 | 0.030 |
Why?
| | Th1 Cells | 1 | 2018 | 139 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1047 | 0.030 |
Why?
| | Genomics | 2 | 2018 | 834 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1496 | 0.030 |
Why?
| | Drug Synergism | 1 | 2018 | 357 | 0.030 |
Why?
| | CpG Islands | 1 | 2018 | 165 | 0.030 |
Why?
| | Epigenomics | 1 | 2018 | 114 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 529 | 0.030 |
Why?
| | Biofilms | 1 | 2020 | 278 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2020 | 356 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 984 | 0.030 |
Why?
| | Cytochrome-c Peroxidase | 1 | 2016 | 1 | 0.030 |
Why?
| | Risk Factors | 3 | 2021 | 10779 | 0.030 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 412 | 0.030 |
Why?
| | Echocardiography | 1 | 2019 | 652 | 0.030 |
Why?
| | Gene Deletion | 2 | 2008 | 389 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2019 | 724 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 82 | 0.030 |
Why?
| | Oxidoreductases | 1 | 2016 | 96 | 0.030 |
Why?
| | Heme | 1 | 2016 | 89 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 612 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1486 | 0.030 |
Why?
| | Monocytes | 1 | 2018 | 538 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2016 | 280 | 0.030 |
Why?
| | Survival Rate | 2 | 2014 | 2089 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 618 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1370 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2021 | 1125 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 556 | 0.030 |
Why?
| | Switzerland | 1 | 2014 | 46 | 0.030 |
Why?
| | Solid-Phase Synthesis Techniques | 1 | 2014 | 10 | 0.030 |
Why?
| | Cohort Studies | 2 | 2016 | 5960 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2014 | 10 | 0.030 |
Why?
| | Base Sequence | 2 | 2008 | 2190 | 0.030 |
Why?
| | Transcription Termination, Genetic | 1 | 2014 | 23 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2019 | 790 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 9 | 0.030 |
Why?
| | Chromatin | 1 | 2018 | 561 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1490 | 0.030 |
Why?
| | Hominidae | 1 | 2014 | 87 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 403 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 386 | 0.020 |
Why?
| | Administration, Intravenous | 1 | 2014 | 170 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2021 | 2496 | 0.020 |
Why?
| | Protein Conformation | 1 | 2016 | 946 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2882 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1045 | 0.020 |
Why?
| | Lung Diseases | 1 | 2020 | 787 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 131 | 0.020 |
Why?
| | Colloids | 1 | 2013 | 61 | 0.020 |
Why?
| | Dielectric Spectroscopy | 1 | 2012 | 1 | 0.020 |
Why?
| | Madagascar | 1 | 2012 | 44 | 0.020 |
Why?
| | Click Chemistry | 1 | 2013 | 51 | 0.020 |
Why?
| | Cisplatin | 1 | 2014 | 334 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2014 | 256 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2014 | 433 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 600 | 0.020 |
Why?
| | Prospective Studies | 3 | 2014 | 7990 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2019 | 2832 | 0.020 |
Why?
| | Coumarins | 1 | 2011 | 17 | 0.020 |
Why?
| | Nitrophenols | 1 | 2011 | 29 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 346 | 0.020 |
Why?
| | Pemetrexed | 1 | 2011 | 38 | 0.020 |
Why?
| | Biphenyl Compounds | 1 | 2011 | 68 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 93 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2273 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1716 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5597 | 0.020 |
Why?
| | Cell Membrane | 1 | 2013 | 706 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2010 | 26 | 0.020 |
Why?
| | 3' Flanking Region | 1 | 2008 | 7 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1833 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 157 | 0.020 |
Why?
| | Adenocarcinoma | 2 | 2007 | 928 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3604 | 0.020 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2007 | 26 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 574 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 965 | 0.020 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2007 | 117 | 0.020 |
Why?
| | Software Design | 1 | 2006 | 25 | 0.020 |
Why?
| | Endogenous Retroviruses | 1 | 2007 | 38 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2145 | 0.020 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2006 | 52 | 0.020 |
Why?
| | Exons | 1 | 2007 | 358 | 0.020 |
Why?
| | Cations | 1 | 2006 | 82 | 0.010 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2006 | 117 | 0.010 |
Why?
| | Precancerous Conditions | 1 | 2007 | 166 | 0.010 |
Why?
| | Alleles | 1 | 2008 | 879 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 307 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 105 | 0.010 |
Why?
| | Patient Compliance | 1 | 2010 | 588 | 0.010 |
Why?
| | Cell Lineage | 1 | 2007 | 376 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2007 | 259 | 0.010 |
Why?
| | BALB 3T3 Cells | 1 | 2004 | 1 | 0.010 |
Why?
| | Biological Evolution | 1 | 2008 | 488 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 372 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 824 | 0.010 |
Why?
| | Neoplasms | 1 | 2018 | 2875 | 0.010 |
Why?
| | DNA Probes | 1 | 2002 | 59 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4271 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 766 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2182 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1489 | 0.010 |
Why?
| | Software | 1 | 2007 | 690 | 0.010 |
Why?
| | Child | 1 | 2022 | 22633 | 0.010 |
Why?
| | Internet | 1 | 2006 | 699 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 824 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3333 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1821 | 0.010 |
Why?
| | Algorithms | 1 | 2006 | 1837 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 17066 | 0.010 |
Why?
| | Palliative Care | 1 | 2004 | 1002 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2006 | 2730 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 4282 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3671 | 0.010 |
Why?
|
|
Meyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|